NCT05640609View on ClinicalTrials.gov

Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

March 10, 2023

Primary Completion Date

November 1, 2024

Study Completion Date

November 1, 2026

Conditions
Stomach Neoplasm
Interventions
COMBINATION_PRODUCT

Capeox regimen combined with Sintilimab and Bevacizumab

Stage Ib：Oxaliplatin +Capecitabine Tablets +Sintilimab +Bevacizumab Stage II：Bevacizumab (the dose determined in phase Ib clinical study)，the dosage of other drugs was the same as before

Trial Locations (1)

Unknown

RECRUITING

Liu Ming, Chengdu

All Listed Sponsors
lead

West China Hospital

OTHER